These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 29019414)
1. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414 [TBL] [Abstract][Full Text] [Related]
2. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772 [TBL] [Abstract][Full Text] [Related]
3. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174 [TBL] [Abstract][Full Text] [Related]
4. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567 [TBL] [Abstract][Full Text] [Related]
5. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309 [TBL] [Abstract][Full Text] [Related]
6. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085 [TBL] [Abstract][Full Text] [Related]
7. THOR is a targetable epigenetic biomarker with clinical implications in breast cancer. Apolónio JD; Dias JS; Fernandes MT; Komosa M; Lipman T; Zhang CH; Leão R; Lee D; Nunes NM; Maia AT; Morera JL; Vicioso L; Tabori U; Castelo-Branco P Clin Epigenetics; 2022 Dec; 14(1):178. PubMed ID: 36529814 [TBL] [Abstract][Full Text] [Related]
8. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer. Mishra NK; Guda C Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671 [TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features. Zhao L; Cui Q; Lu Z; Chen J Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082 [TBL] [Abstract][Full Text] [Related]
12. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Ko E; Seo HW; Jung ES; Kim BH; Jung G Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952 [TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792 [TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging. Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Pedersen IS; Krarup H; Thorlacius-Ussing O Int J Cancer; 2017 Dec; 141(12):2489-2497. PubMed ID: 28857158 [TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606 [TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas. Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771 [TBL] [Abstract][Full Text] [Related]
18. Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Kumari A; Srinivasan R; Vasishta RK; Wig JD Ann Surg Oncol; 2009 Apr; 16(4):1051-9. PubMed ID: 19194757 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Zhuang H; Zhou Z; Ma Z; Li Z; Liu C; Huang S; Zhang C; Hou B J Cell Mol Med; 2020 Nov; 24(22):13481-13493. PubMed ID: 33073486 [TBL] [Abstract][Full Text] [Related]
20. The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC). Li JJ; Zheng PCJ; Wang YZ World J Surg Oncol; 2017 Jun; 15(1):114. PubMed ID: 28587656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]